Bristol Myers BMY recently announced that it will acquire privately held biotechnology company Orbital Therapeutics for $1.5 ...

Iovance Biotherapeutics was the first drug developer to win FDA approval of an immune cell/T-cell therapy. The underlying ...

NRIX stock is rated Strong Buy as bexobrutideg advances in CLL trials. See here for NRIX stock's milestones, market potential ...

Readers respond to a guest essay by Keith Humphreys and an article about a fentanyl death. To the Editor: Re “Forced Drug Treatment Isn’t Horrific. It’s a Relief,” by Keith Humphreys (Opinion guest ...

SHANGHAI, Aug. 6, 2025 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced that ...

Hepatic encephalopathy (HE) occurs either from portosystemic shunting 3 or is caused by hepatic lipidosis from amino acid imbalance. HE manifests as ptyalism, dullness, ataxia, and/or seizures.4 ...

A real-world comparative study of hypertension (HTN) and time to treatment failure (TTF) with acalabrutinib versus ibrutinib in treatment-naive Medicare-eligible patients with chronic lymphocytic ...

In the past 25 years — from 2000 to 2024 — we have witnessed a revolution in the management, treatment, and outcome of what used to be the most lethal hematologic cancer: Philadelphia ...

Work described in this story was made possible in part by federal funding supported by taxpayers. At Harvard Medical School, the future of efforts like this — done in service to humanity — now hangs ...

Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. Adoptive cell therapy based ...

Which Is the Best Tyrosine Kinase Inhibitor for Newly Diagnosed Chronic Myelogenous Leukemia? Chronic lymphocytic leukemia (CLL) remains an incurable disease, except in rare cases treated with ...